1-4 of 4
James McCloskey
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: final results

Clinical Trials & Observations
Abdulraheem Yacoub, Uma Borate, Raajit K. Rampal, Haris Ali, Eunice S. Wang, Aaron T. Gerds, Gabriela Hobbs, Marina Kremyanskaya, Elliott Winton, Casey O’Connell, Swati Goel, Stephen T. Oh, Gary Schiller, James McCloskey, Jeanne Palmer, Houston Holmes, Steven Hager, Albert Assad, Susan Erickson-Viitanen, Feng Zhou, Naval Daver
Journal: Blood Advances
Blood Adv (2024) 8 (6): 1515–1528.
https://doi.org/10.1182/bloodadvances.2023011620
Published: 2024
Includes: Supplemental data
Journal Articles

Aspacytarabine for the treatment of patients with AML unfit for intensive chemotherapy: a phase 2 study

Clinical Trials & Observations
Jessica K. Altman, Tsila Zuckerman, Jamie Koprivnikar, James McCloskey, Vamsi Kota, Michael Keng, Olga Frankfurt, Yasmin Abaza, Dale L. Bixby, Ashkan Emadi, Micah Burch, Bhavana Bhatnagar, Selina M. Luger, Mary-Elizabeth Percival, Ofir Wolach, Michael Craig, Chezi Ganzel, Gail Roboz, Itai Levi, Anna Gourevitch, Liat Flaishon, Shoshi Tessler, Chen Blumberg, Stela Gengrinovitch, Ruth Ben Yakar, Jacob M. Rowe
Journal: Blood Advances
Blood Adv (2023) 7 (24): 7494–7500.
https://doi.org/10.1182/bloodadvances.2023010943
Published: 2023
Journal Articles

Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure

Clinical Trials & Observations
Brian J. Ball, Christopher A. Famulare, Eytan M. Stein, Martin S. Tallman, Andriy Derkach, Mikhail Roshal, Saar I. Gill, Benjamin M. Manning, Jamie Koprivnikar, James McCloskey, Rebecca Testi, Thomas Prebet, Najla H. Al Ali, Eric Padron, David A. Sallman, Rami S. Komrokji, Aaron D. Goldberg
Journal: Blood Advances
Blood Adv (2020) 4 (13): 2866–2870.
https://doi.org/10.1182/bloodadvances.2020001482
Published: 2020
Includes: Supplemental data
Journal Articles

Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia

Clinical Trials & Observations
Nitin Jain, Wendy Stock, Amer Zeidan, Ehab Atallah, James McCloskey, Leonard Heffner, Benjamin Tomlinson, Bhavana Bhatnagar, Jay Feingold, David Ungar, Grace Chao, Xiaoyan Zhang, Yajuan Qin, Karin Havenith, Hagop Kantarjian, Matthew J. Wieduwilt
Journal: Blood Advances
Blood Adv (2020) 4 (3): 449–457.
https://doi.org/10.1182/bloodadvances.2019000767
Published: 2020
Includes: Supplemental data